相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney
Dario Giugliano et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
GLP-1RAs and SGLT2is Reduce Cardiovascular Events Independent of Reductions of Systolic Blood Pressure and Body Weight: A Meta-Analysis with Meta-Regression
Mei Qiu et al.
DIABETES THERAPY (2020)
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
Thomas A. Zelniker et al.
CIRCULATION (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial
Kenneth W. Mahaffey et al.
CIRCULATION (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker et al.
LANCET (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program
Brendon L. Neuen et al.
CIRCULATION (2018)
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
Karin Radholm et al.
CIRCULATION (2018)
SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis
Man Guo et al.
DIABETES OBESITY & METABOLISM (2018)
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
Christoph Wanner et al.
CIRCULATION (2018)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)